title: Antivascular endothelial growth factor treatments for neovascular age-related macular degeneration save sight, but does everyone get treated?
authors.forename: Robert P
authors.initials: RP
authors.lastname: Finger
authors.forename: Robyn H
authors.initials: RH
authors.lastname: Guymer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001315:Australia; D001766:Blindness / Q000517:prevention & control; D016208:Databases, Factual; D005260:Female; D006297:Health Services Accessibility / Q000706:statistics & numerical data / Q000639:trends*; D006801:Humans; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D017063:Outcome Assessment, Health Care; D000069579:Ranibizumab; D018570:Risk Assessment; D012720:Severity of Illness Index; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042442:Vascular Endothelial Growth Factors; D000069579:Ranibizumab